AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01516203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol, isoniazid, pyrazinamide, rifampin
Description: Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
Study NCT00380120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium warfarin
Description: dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
Study NCT00380120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium warfarin
Description: dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
Study NCT00380120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium warfarin
Description: As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
Study NCT00380120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium warfarin
Description: As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
Study NCT02208570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV>14%
Description: Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
Study NCT02208570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volume loading
Description: Hydroxyethyl starch solution 6ml/kg iv injection
Study NCT02208570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV<14%
Description: Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
Study NCT02783820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 40 mg
Study NCT02783820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match MMV390048 40 mg
Study NCT02783820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 80 mg
Study NCT02783820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match MMV390048 80 mg
Study NCT02783820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 120 mg
Study NCT02783820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match MMV390048 120 mg
Study NCT00201864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg orally per day
Study NCT00201864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg IM starting on Day 8 and then every 28 days.
Study NCT02020499 — intervention group
Intervention type: DRUG
Intervention: Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
Description: Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
Study NCT04610216 — intervention group
Intervention type: DEVICE
Intervention: Naida CI M hearing device
Description: speech intelligibility measurement with Naida CI M hearing device
Study NCT02890238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene citrate
Description: 50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
Study NCT02890238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: 50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
Study NCT02890238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: 20mg tab from 7th-11th day of the same cycle orally 3times/day
Study NCT02890238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tab from 7th-11th day of the same cycle orally 3times/day
Study NCT02429687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02429687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02429687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
Study NCT02429687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
Study NCT02429687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
Study NCT01333878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous Abatacept
Description: Subcutaneous Abatacept 125 mg once weekly for 6 months
Study NCT00956696 — intervention group
Intervention type: DRUG
Intervention: topiramate
Description: oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
Study NCT04662671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD-X19
Description: Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
Study NCT04662671 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RD-X19
Description: Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
Study NCT03739294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication
Study NCT03596281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 400 or 300 mg Q3W IV
Study NCT03596281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: 15 or 20 or 30 mg/m² Q3W IV
Study NCT01862991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: Dilapan-S osmotic cervical dilators inserted through the internal os.
Study NCT01862991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: Dilapan-S osmotic cervical dilators inserted through the internal os.
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccal misoprostol 90 pre-op
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccal misoprostol 90 pre-op
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg buccal misoprostol 90 pre-op
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: 200 mcg Mifepristone orally
Study NCT01862991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mcg Mifepristone orally
Study NCT02047565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg edoxaban
Study NCT02047565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180mg edoxaban
Study NCT02047565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 IU/kg Beriplex P/N
Study NCT02047565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 IU/kg Beriplex P/N
Study NCT02047565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 IU/kg Beriplex P/N
Study NCT01015807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Placebo
Description: 2 x 20mL 0.9% NaCl
Study NCT01015807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine Placebo
Description: 2 x 1mL 0.9% NaCl
Study NCT01015807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Placebo
Description: 2 x 1mL 0.9% NaCl
Study NCT01015807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
Study NCT01015807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 2 x 1ml Clonidine = 150 µg Clonidine
Study NCT02819856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg SPI-1005 bid po x 21d
Study NCT02819856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005 Ebselen 200mg Capsule x1
Description: 200 mg SPI-1005 bid po x21d
Study NCT02819856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005 Ebselen 200mg Capsule x2
Description: 400 mg SPI-1005 bid po x 21d
Study NCT02819856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1005 Ebselen 200mg Capsule x3
Description: 600 mg SPI-1005 bid po x 21d
Study NCT02762344 — intervention group
Intervention type: DRUG
Intervention: heparin
Description: routinary heparin administration during coronary angiography/PCI
Study NCT02075021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02075021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study NCT03350113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood sampling for analysis
Description: Blood Sampling for Analysis
Study NCT02839122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Study NCT02839122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study NCT03221504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longer therapy duration
Description: Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
Study NCT03221504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter therapy duration
Description: Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
Study NCT03176095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study NCT03176095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01114750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin in dextran matrix capsule (and placebo)
Description: Single dose capsule (and placebo)
Study NCT01114750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin in dextran matrix capsule (and placebo)
Description: Single dose capsule (and placebo)
Study NCT01486615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: meloset (melatonin)
Description: 3 mg melatonin tablet 1-2 hour prior surgery
Study NCT01486615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: stresnil ( melatonin and alprazolam)
Description: 3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
Study NCT01486615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: (alprax) alprazolam
Description: 0.5 mg alprazolam
Study NCT01486615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: similar looking placebo tablet
Study NCT01999062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMRT + CT + MR scan
Study NCT00794001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data analysis and Feedback
Description: Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
Study NCT02444988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline will be used whenever an isotonic crystalloid is ordered
Study NCT02444988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically-balanced isotonic crystalloid
Description: Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Study NCT03375125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: L. reuteri DSM 17938 \& L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
Study NCT03375125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
Study NCT03465449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKD-EDU
Description: Palliative Care based coaching intervention for support with dialysis-related decision making.
Study NCT03465449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Nephrologist based usual care
Study NCT04242420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genotyping
Description: Genotyping for single nucleotide polymorphisms for Connexin 37\&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
Study NCT04242420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung function
Description: Spirometry,
Study NCT04242420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microbiology
Description: Bacterial culture from Sputum or swab
Study NCT04242420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Interleukin-8 assay (via chemiluminescence) blood cell count
Study NCT04242420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Induced Sputum
Description: Interleukin-8 assay (via chemiluminescence) blood cell count
Study NCT01040767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training in basic ultrasound and the EFAST
Description: Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
Study NCT04343443 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
Study NCT04343443 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
Description: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
Study NCT04343443 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample collection will be performed before discharge from hospital
Study NCT04343443 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone interview
Description: Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
Study NCT04343443 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study NCT01517243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
Study NCT01517243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
Study NCT01230606 — intervention group
Intervention type: OTHER
Intervention: discharge vs. overnight stay
Description: At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
Study NCT01383057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser
Description: Using the Femtosecond Laser to make a clear corneal incision.
Study NCT03966079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator
Description: Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
Study NCT01751815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Description: Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
Study NCT01751815 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo-TENS
Description: Patients randomized to the control group will receive placebo-TENS at the same acupoints.
Study NCT02906085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Study NCT02906085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline
Study NCT02281175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
Study NCT02281175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a weekly physician intervention
Description: Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
Study NCT03693274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BreathAware for Pain Management
Description: Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
Study NCT03366220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
Study NCT03366220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced crystalloids
Description: Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
Study NCT01250119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg daily, orally
Study NCT03393338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DM I-TEAM
Description: DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
Study NCT03303677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Nasal
Description: topical nasal saline rinses